Nexalin Technology, Inc. (NXL)
Automate Your Wheel Strategy on NXL
With Tiblio's Option Bot, you can configure your own wheel strategy including NXL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NXL
- Rev/Share 0.0098
- Book/Share 0.1747
- PB 6.9816
- Debt/Equity 0.0
- CurrentRatio 4.5596
- ROIC -3.7363
- MktCap 20957073.0
- FreeCF/Share -0.3425
- PFCF -4.5986
- PE -1.8979
- Debt/Assets 0.0
- DivYield 0
- ROE -2.7796
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3
Published: May 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin's game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology.
Read More
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced underwritten public offering of 3,850,000 shares of its common stock at a public offering price of $1.30 per share. The gross proceeds from the offering to Nexalin were approximately $5.0 million, before deducting underwriting discounts and commissions and other offering expenses.
Read More
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company initiates formal regulatory engagement on trial design for Alzheimer's, dementia, and MCI indications Company initiates formal regulatory engagement on trial design for Alzheimer's, dementia, and MCI indications
Read More
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™
Read More
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced its support for the Health Tech Investment Act (S. 1399) — bipartisan legislation introduced in the United States Senate that would expand Medicare reimbursement opportunities for FDA-cleared or approved medical devices that incorporate artificial intelligence (AI) or machine learning.
Read More
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
Published: April 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
Patent Approval Reinforces Nexalin's Leadership in Non-Invasive Brain Stimulation for Addiction Treatment Patent Approval Reinforces Nexalin's Leadership in Non-Invasive Brain Stimulation for Addiction Treatment
Read More
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET.
Read More
About Nexalin Technology, Inc. (NXL)
- IPO Date 2022-09-16
- Website https://www.nexalin.com
- Industry Medical - Devices
- CEO Mr. Mark White
- Employees 6